This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 955756.

Dr. Wiebke Saal

F. Hoffmann- La Roche AG, Pharmaceutical R&D (Roche), Switzerland

Scientist at Roche

Supervisor of ESR2


Wiebke Saal graduated as a pharmacist at the University of Heidelberg in 2013 and completed her PhD in Pharmaceutical Technology at the University of Basel, Switzerland, in 2017. Thereafter, she joined F. Hoffmann – La Roche as a Scientist in the preformulation department. Her research focus is on drug-excipients interactions especially with regards to solubility enhancement and solid state properties.

Selected Publications

  • Saal, N. Wyttenbach, J. Alsenz, M. Kuentz: Interactions of dimethylaminoethyl methacrylate copolymer with non-acidic drugs demonstrated high solubilization in vitro and pronounced sustained release in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2018;125:68-75
  • Saal, N. Wyttenbach, J. Alsenz, M. Kuentz: The quest for exceptional drug solubilization in diluted surfactant solutions and consideration of residual solid state. European Journal of Pharmaceutical Sciences, 2018;111:96-103
  • Saal, A. Ross, N. Wyttenbach, J. Alsenz, M. Kuentz; A systematic study of molecular interactions of anionic drugs with a dimethylaminoethyl methacrylate copolymer regarding solubility enhancement. Molecular Pharmaceutics,2017;14(4):1243-1250
  • Wyttenbach, W. Kirchmeyer, J. Alsenz, M. Kuentz; Theoretical considerations of the Prigogine–Defay ratio with regard to the glass-forming ability of drugs from undercooled melts. Molecular Pharmaceutics, 2016;13(1):241-250